> top > docs > PMC:7696151 > spans > 47476-51400 > annotations

PMC:7696151 / 47476-51400 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1393 3611-3615 Gene denotes IL-6 Gene:3569
1394 3620-3625 Gene denotes TNF-α Gene:7124
1395 3863-3868 Gene denotes IFN-α Gene:3439
1396 2472-2475 Gene denotes lpr Gene:14102
1397 909-917 Species denotes patients Tax:9606
1398 940-946 Species denotes People Tax:9606
1399 1179-1187 Species denotes patients Tax:9606
1400 2476-2480 Species denotes mice Tax:10090
1401 3214-3222 Species denotes patients Tax:9606
1402 3671-3679 Species denotes patients Tax:9606
1403 180-183 Chemical denotes HCQ MESH:D006886
1404 290-293 Chemical denotes HCQ MESH:D006886
1405 495-498 Chemical denotes HCQ MESH:D006886
1406 799-802 Chemical denotes HCQ MESH:D006886
1407 1142-1145 Chemical denotes HCQ MESH:D006886
1408 1248-1251 Chemical denotes HCQ MESH:D006886
1409 1361-1364 Chemical denotes HCQ MESH:D006886
1410 1448-1451 Chemical denotes HCQ MESH:D006886
1411 1677-1680 Chemical denotes HCQ MESH:D006886
1412 1963-1966 Chemical denotes HCQ MESH:D006886
1413 2351-2354 Chemical denotes HCQ MESH:D006886
1414 2438-2441 Chemical denotes HCQ MESH:D006886
1415 2541-2544 Chemical denotes HCQ MESH:D006886
1416 2629-2633 Chemical denotes Treg
1417 2989-2992 Chemical denotes HCQ MESH:D006886
1418 3276-3279 Chemical denotes HCQ MESH:D006886
1419 3435-3438 Chemical denotes HCQ MESH:D006886
1420 3681-3684 Chemical denotes HCQ MESH:D006886
1421 9-28 Disease denotes lupus erythematosus MESH:D008180
1422 34-88 Disease denotes multisystemic autoimmune chronic inflammatory disorder MESH:D019693
1423 323-342 Disease denotes lupus erythematosus MESH:D008180
1424 668-678 Disease denotes thrombotic MESH:D013927
1425 933-938 Disease denotes lupus MESH:D008180
1426 1036-1047 Disease denotes skin rashes MESH:D005076
1427 1049-1058 Disease denotes arthritis MESH:D001168
1428 1064-1070 Disease denotes ulcers MESH:D014456
1429 1159-1178 Disease denotes lupus erythematosus MESH:D008180
1430 1408-1413 Disease denotes lupus MESH:D008180
1431 1570-1575 Disease denotes lupus MESH:D008180
1432 2210-2229 Disease denotes autoimmune diseases MESH:D001327
1433 2248-2253 Disease denotes lupus MESH:D008180
1434 2490-2508 Disease denotes lupus-like disease MESH:D008180
1435 3019-3049 Disease denotes attenuated kidney inflammation MESH:C538265
1436 3243-3248 Disease denotes lupus MESH:D008180
1437 3385-3398 Disease denotes lupus disease MESH:D008180
1438 3665-3670 Disease denotes lupus MESH:D008180
1439 3900-3905 Disease denotes lupus MESH:D008180

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T82 0-28 Phenotype denotes Systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T83 985-1008 Phenotype denotes constitutional symptoms http://purl.obolibrary.org/obo/HP_0025142
T84 1049-1058 Phenotype denotes arthritis http://purl.obolibrary.org/obo/HP_0001369
T85 2210-2229 Phenotype denotes autoimmune diseases http://purl.obolibrary.org/obo/HP_0002960
T86 3030-3049 Phenotype denotes kidney inflammation http://purl.obolibrary.org/obo/HP_0000123

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T308 0-162 Sentence denotes Systemic lupus erythematosus is a multisystemic autoimmune chronic inflammatory disorder that mainly involves joints, mucosae, skin, and endothelial vessels [90].
T309 163-252 Sentence denotes For a long time, HCQ has played a marginal role in the overall management of the disease.
T310 253-408 Sentence denotes Since the 90s, the first evidence of HCQ effectiveness in controlling lupus erythematosus manifestations allowed its employment as a first-line medicament.
T311 409-558 Sentence denotes Although it was not recommended in single therapy, the immunomodulating properties of HCQ seem to play an important role in the disease pathogenesis.
T312 559-691 Sentence denotes It is associated with a decrement of exacerbation events, as well as protective effects towards vascular and thrombotic events [85].
T313 692-939 Sentence denotes Indeed, a 24-week randomized, double-blind placebo-controlled trial demonstrated that the discontinuing of HCQ treatment (100–400 mg/kg/day for at least six months) increased the risk of exacerbations by 2.5 times in patients with quiescent lupus.
T314 940-1076 Sentence denotes People who interrupted the therapy exhibited constitutional symptoms of the disease, as well as skin rashes, arthritis, and ulcers [83].
T315 1077-1292 Sentence denotes A long-term randomized study evaluated the withdrawal effects of HCQ on quiescent lupus erythematosus patients, revealing that a reduction by up to 57% is associated with HCQ maintaining treatment (272 mg/day) [84].
T316 1293-1414 Sentence denotes A case-control study was carried out in order to define the role of HCQ in the survival of individuals affected by lupus.
T317 1415-1592 Sentence denotes The positive correlation between HCQ and survival led to the consideration of this drug as a great therapeutic option at the proper dose (6.5 mg/kg/bw) in lupus management [85].
T318 1593-1822 Sentence denotes If these clinical trials demonstrated the advantages of keeping up the therapy with HCQ in preventing disease exacerbations, doubts persisted about the efficacy of this treatment in the control of more severe clinical forms [83].
T319 1823-1997 Sentence denotes As the important role of the imbalance between immune cell populations, several preclinical and clinical studies have evaluated the role of HCQ in restoring this equilibrium.
T320 1998-2254 Sentence denotes In particular, elevated levels of effector lymphocyte T (Th17) that mediate the autoimmune answer and decreased levels of regulatory lymphocyte T (Treg) that guarantees the immune homeostasis, may be observed in autoimmune diseases, in particular in lupus.
T321 2255-2347 Sentence denotes Lately, autophagy had risen among the emerging strategies to reestablish the immune balance.
T322 2348-2509 Sentence denotes As HCQ is a well-known autophagy inhibitor, An, N. et al. [86] evaluated the influence of HCQ intake (100 mg/kg/day) in MRL/lpr mice with the lupus-like disease.
T323 2510-2660 Sentence denotes After four weeks of treatment, HCQ clearly restored the immune balance, by both inhibiting Th17 response and enhancing Treg immunosuppressive effects.
T324 2661-2943 Sentence denotes The levels of autoantibodies and the expression of inflammatory cytokines, mainly in Th17 cells, were remarkably lowered, due to the inhibition of the activated autophagy, as demonstrated by the increase of autophagic flux marker expression in Th17 and Treg, compared with controls.
T325 2944-3128 Sentence denotes This randomized trial further evidenced that HCQ treatment also remarkably attenuated kidney inflammation, by limiting the migration of lymphoplasmacytic cells into renal tissues [86].
T326 3129-3280 Sentence denotes Preclinical outcomes have been confirmed by a prospective cohort study, involving 41 patients with a diagnosis of lupus treated with 400 mg/day of HCQ.
T327 3281-3631 Sentence denotes Dysregulated cytokine and autoantibody production, deriving from high autoreactivity that characterizes lupus disease, has been restored by two months of HCQ administration, demonstrating its ability in modulating inflammatory response, with normalized complement activity and reduced levels of pro-inflammatory cytokines, mainly IL-6 and TNF-α [87].
T328 3632-3924 Sentence denotes In a multiethnic US cohort on 35 lupus patients, HCQ treatment resulted in significant clinical benefits towards disease progression, probably due to the inhibition of toll-like receptor activation, resulting in down-regulation of IFN-α, which plays a pivotal role in lupus pathogenesis [88].